New Antibiotics in the Therapy of Osteomyelitis
Journal Title: Mediterranean Journal of Infection, Microbes and Antimicrobials - Year 2017, Vol 6, Issue 1
Abstract
Osteomyelitis is probably the oldest known infection in the history of life. It can develop secondary to local tissue disruption, ischemia and associated chronic wounds or via hematogenous infection. Although it has been known to the medical community for a long time, treatment remains challenging. Detection of the microbial agent remains crucial for the associated antibiotic therapy. Also, tissue specimens for culture and histology must be obtained. Several factors such as biofilm formation, resistance development and special virulence factors can impede the efficiency of the antibiotic treatment. In the last two decades, developments of antibiotic agents with available data in the field of osteomyelitis primarily include brilacidin, ceftaroline, ceftobiprole, dalbavancin, daptomycin, tedizolid, telavancin, tigecycline. Many of them are not on the market, or under study, or only found in selected countries. However, they are expected to become more accessible in coming years.
Authors and Affiliations
Stefanie HIRSIGER, İlke ILGAZ, İlker UÇKAY
Keywords
Related Articles
- EP ID EP689360
- DOI 10.4274/mjima.2017.15
- Views 129
- Downloads 0
Not So Innocent: Thrombocytopenia After One Dose of Rifampicin
No Abstract
EDİTÖRYAL
No Abstract
Infection Control Bundles for the Prevention of Hospital Infections
The incidence of hospital-acquired infections increases due to the rising use of invasive procedures and increased length of hospital stay. The incidence of colonization and infection with multidrug-resistant microorgani...
EDITORIAL/ EDİTÖRYAL
No Abstract
A Case Report: Mycobacterium fortuitum Spondylodiscitis
No Abstract